About senti biosciences holdings inc - SNTI
Operates as a holding company whose subsidiary develops cell and gene therapies for cancer diseases
SNTI At a Glance
Senti Biosciences Holdings, Inc.
2 Corporate Drive
South San Francisco, California 94080
| Phone | N/A | Revenue | 22.00K | |
| Industry | Biotechnology | Net Income | -61,438,000.00 | |
| Sector | Health Technology | Employees | 39 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SNTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,062.851 |
| Price to Book Ratio | 5.746 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.597 |
| Enterprise Value to Sales | 1,629.715 |
| Total Debt to Enterprise Value | 0.806 |
SNTI Efficiency
| Revenue/Employee | 564.103 |
| Income Per Employee | -1,575,333.333 |
| Receivables Turnover | 0.014 |
| Total Asset Turnover | 0.00 |
SNTI Liquidity
| Current Ratio | 1.666 |
| Quick Ratio | 1.666 |
| Cash Ratio | 1.175 |
SNTI Profitability
| Gross Margin | -16,431.818 |
| Operating Margin | -289,668.182 |
| Pretax Margin | -279,263.636 |
| Net Margin | -279,263.636 |
| Return on Assets | -82.432 |
| Return on Equity | -218.082 |
| Return on Total Capital | -178.184 |
| Return on Invested Capital | -112.942 |
SNTI Capital Structure
| Total Debt to Total Equity | 516.926 |
| Total Debt to Total Capital | 83.791 |
| Total Debt to Total Assets | 56.402 |
| Long-Term Debt to Equity | 421.56 |
| Long-Term Debt to Total Capital | 68.332 |